Duffy antigen receptor for chemokines gene polymorphisms and malaria in Mangaluru, India.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
24 Sep 2019
Historique:
received: 02 04 2019
accepted: 16 09 2019
entrez: 26 9 2019
pubmed: 26 9 2019
medline: 29 1 2020
Statut: epublish

Résumé

Duffy blood group antigens serve as receptors for Plasmodium vivax invasion into erythrocytes, and they are determined by polymorphisms of the Duffy antigen receptor for chemokines (DARC), also known as Fy glycoprotein (FY). Duffy negativity, i.e., absence of the antigens, protects against P. vivax infection and is rare among non-African populations. However, data on DARC polymorphisms and their impact on Plasmodium infection in India are scarce. In a case-control study among 909 malaria patients and 909 healthy community controls in Mangaluru, southwestern India, DARC polymorphisms T-33C (rs2814778), G125A (rs12075), C265T (rs34599082), and G298A (rs13962) were genotyped. Associations of the polymorphisms with the odds of malaria, parasite species and manifestation were assessed. Among patients, vivax malaria (70%) predominated over falciparum malaria (9%) and mixed species infections (21%). DARC T-33C was absent and C265T was rare (1%). FYB carriage (deduced from DARC G125A) was not associated with the risk of malaria per se but it protected against severe falciparum malaria (P = 0.03), and hospitalization (P = 0.006) due to falciparum malaria. Vice versa, carriage of DARC 298A was associated with increased odds of malaria (aOR, 1.46 (1.07-1.99), P = 0.015) and vivax malaria (aOR, 1.60 (1.14-2.22), P = 0.006) and with several reported symptoms and findings of the patients. This report from southern India is the first to show an independent effect of the DARC 298A polymorphism on the risk of malaria. Functional studies are required to understand the underlying mechanism. Moreover, FYB carriage appears to protect against severe falciparum malaria in southern India.

Sections du résumé

BACKGROUND BACKGROUND
Duffy blood group antigens serve as receptors for Plasmodium vivax invasion into erythrocytes, and they are determined by polymorphisms of the Duffy antigen receptor for chemokines (DARC), also known as Fy glycoprotein (FY). Duffy negativity, i.e., absence of the antigens, protects against P. vivax infection and is rare among non-African populations. However, data on DARC polymorphisms and their impact on Plasmodium infection in India are scarce.
METHODS METHODS
In a case-control study among 909 malaria patients and 909 healthy community controls in Mangaluru, southwestern India, DARC polymorphisms T-33C (rs2814778), G125A (rs12075), C265T (rs34599082), and G298A (rs13962) were genotyped. Associations of the polymorphisms with the odds of malaria, parasite species and manifestation were assessed.
RESULTS RESULTS
Among patients, vivax malaria (70%) predominated over falciparum malaria (9%) and mixed species infections (21%). DARC T-33C was absent and C265T was rare (1%). FYB carriage (deduced from DARC G125A) was not associated with the risk of malaria per se but it protected against severe falciparum malaria (P = 0.03), and hospitalization (P = 0.006) due to falciparum malaria. Vice versa, carriage of DARC 298A was associated with increased odds of malaria (aOR, 1.46 (1.07-1.99), P = 0.015) and vivax malaria (aOR, 1.60 (1.14-2.22), P = 0.006) and with several reported symptoms and findings of the patients.
CONCLUSION CONCLUSIONS
This report from southern India is the first to show an independent effect of the DARC 298A polymorphism on the risk of malaria. Functional studies are required to understand the underlying mechanism. Moreover, FYB carriage appears to protect against severe falciparum malaria in southern India.

Identifiants

pubmed: 31551092
doi: 10.1186/s12936-019-2966-9
pii: 10.1186/s12936-019-2966-9
pmc: PMC6760058
doi:

Substances chimiques

ACKR1 protein, human 0
Duffy Blood-Group System 0
Receptors, Cell Surface 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

328

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : GRK 1673
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK 2046

Références

Transfusion. 2000 Mar;40(3):310-20
pubmed: 10738032
Semin Hematol. 2000 Apr;37(2):122-9
pubmed: 10791881
Science. 1975 Aug 15;189(4202):561-3
pubmed: 1145213
FASEB J. 2002 Jul;16(9):1093-5
pubmed: 12087071
Lancet Infect Dis. 2002 Aug;2(8):472-8
pubmed: 12150846
Am J Hum Genet. 2005 Aug;77(2):171-92
pubmed: 16001361
Hum Hered. 1991;41(4):231-5
pubmed: 1783411
Cell Host Microbe. 2008 Jul 17;4(1):52-62
pubmed: 18621010
Inflamm Res. 2009 Aug;58(8):431-5
pubmed: 19290478
Parasitol Res. 2010 Apr;106(5):1049-53
pubmed: 20162434
Nat Commun. 2011;2:266
pubmed: 21468018
Malar J. 2011 Sep 19;10:271
pubmed: 21929748
Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20113-8
pubmed: 22123959
PLoS One. 2012;7(5):e36692
pubmed: 22615793
PLoS Negl Trop Dis. 2012;6(6):e1710
pubmed: 22745844
PLoS One. 2012;7(9):e45219
pubmed: 23028857
Science. 2012 Dec 7;338(6112):1348-51
pubmed: 23224555
Indian J Med Res. 2013 Mar;137(3):521-6
pubmed: 23640559
Commun Integr Biol. 2013 May 1;6(3):e23653
pubmed: 23710276
Blood Transfus. 2018 Jan;16(1):93-100
pubmed: 28151395
Malar J. 2018 Aug 29;17(1):313
pubmed: 30157861
NPJ Vaccines. 2018 Sep 28;3:48
pubmed: 30302285
Front Immunol. 2018 Dec 19;9:3005
pubmed: 30619354
Hum Hered. 1986;36(1):31-6
pubmed: 3512422
Science. 1993 Aug 27;261(5125):1182-4
pubmed: 7689250
N Engl J Med. 1976 Aug 5;295(6):302-4
pubmed: 778616
Mol Biochem Parasitol. 1993 Apr;58(2):283-92
pubmed: 8479452
Biochem Biophys Res Commun. 1996 May 24;222(3):852-9
pubmed: 8651934

Auteurs

Prabhanjan P Gai (PP)

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Institute of Tropical Medicine and International Health, Berlin, Germany. prabhanjangai@hotmail.com.

Welmoed van Loon (W)

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Institute of Tropical Medicine and International Health, Berlin, Germany.

Konrad Siegert (K)

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Institute of Tropical Medicine and International Health, Berlin, Germany.

Jakob Wedam (J)

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Institute of Tropical Medicine and International Health, Berlin, Germany.

Suyamindra S Kulkarni (SS)

Karnataka Institute for DNA Research, Dharwad, Karnataka, India.

Rashmi Rasalkar (R)

Karnataka Institute for DNA Research, Dharwad, Karnataka, India.

Archith Boloor (A)

Kasturba Medical College, Mangalore, India.
Manipal Academy of Higher Education, Manipal, Karnataka, India.

Arun Kumar (A)

District Vector Borne Disease Control Programme Office, Dakshina Kannada, Mangaluru, Karnataka, India.

Animesh Jain (A)

Kasturba Medical College, Mangalore, India.
Manipal Academy of Higher Education, Manipal, Karnataka, India.

Chakrapani Mahabala (C)

Kasturba Medical College, Mangalore, India.
Manipal Academy of Higher Education, Manipal, Karnataka, India.

Shantaram Baliga (S)

Kasturba Medical College, Mangalore, India.
Manipal Academy of Higher Education, Manipal, Karnataka, India.

Rajeshwari Devi (R)

Wenlock Hospital, Mangaluru, Karnataka, India.

Damodara Shenoy (D)

Kasturba Medical College, Mangalore, India.
Manipal Academy of Higher Education, Manipal, Karnataka, India.

Pramod Gai (P)

Karnataka Institute for DNA Research, Dharwad, Karnataka, India.

Frank P Mockenhaupt (FP)

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Institute of Tropical Medicine and International Health, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH